Woebot Health, maker of an AI-powered mental health chatbot, announced Tuesday it has raised $9.5 million from Leaps by Bayer.

The strategic investment comes about eight months after the company said it had scored $90 million in Series C funding. Last year, Woebot received FDA Breakthrough Device Designation for its digital therapeutic treating postpartum depression.

"Woebot Health’s mission and products are well aligned with our leaps number 5 and 10 – to protect the brain and the mind, and to transform health with data," Dr. Jürgen Eckhardt, head of Leaps by Bayer, said in a statement.

"With its deep focus on clinical evidence and unique AI-based platform and products, Woebot Health is forging a new frontier in behavioral health at a critical time in our world. We’re excited to support endeavors that will make tech-supported continuous care a reality for all."

Founded in 2017, Woebot puts its total raise at $123.5 million.

OpenLoop, which provides staffing and support to digital health companies launching virtual care services, scooped up $8 million in Series A funding. 

The round was led by SpringTide Ventures with participation from ManchesterStory, Next Level Ventures, Panoramic Ventures, ISA Ventures and some strategic healthcare syndicates. OpenLoop said the Series A brings its total raise to about $11 million. 

The startup offers regulatory and legal assistance, provider staffing, telehealth infrastructure, administrative services and revenue cycle management to companies building out virtual care services. It says it will use the investment to expand its tech infrastructure and hire new staffers for its practice management and revenue cycle teams.

Prescription digital therapeutic company metaMe Health raised $2.2 million in a bridge funding round led by Hyde Park Angels with participation from individual investors.

The company will use the funding to prepare for the market launch of Regulora, a prescription digital therapeutic aimed at treating abdominal pain associated with irritable bowel syndrome in adults. The therapeutic received FDA 510(k) clearance late last year. metaMe said it plans to release Regulora in the second half of 2022.

"We are thrilled to have the support of HPA as we prepare for the launch of Regulora," CEO Tim Rudolphi said in a statement. "We believe that Regulora is poised to change the lives of the millions of Americans who suffer from IBS. HPA’s support provides the capital and expertise we need to prepare for launch and raise our Series A funding."